AdaptHealth : Q1 Financial document - (AHCO 2026.05.05 8K EX 991)
AHCO
Published on 05/05/2026 at 09:35 am EDT
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONSHOHOCKEN, Pa. - May 5, 2026 - AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical
equipment, medical supplies, and related services, announced today financial results for the first quarter ended March 31, 2026.
Completed the largest de novo expansion in the history of the home medical equipment industry, meeting an aggressive go live schedule to become the exclusive provider to the more than 10 million members of our new strategic partner.
The acceleration of the transition came with $12 million of elevated labor expense, of which the majority was variable and is expected to normalize by the end of the second quarter. The remainder was elevated wages and benefits that the Company expects to decline as it aligns the operating model to the service requirements.
Advanced digital patient engagement and expanded self-service capabilities, growing registered myApp users to 412,000, up 26% from the fourth quarter of 2025.
In April 2026, completed a $1.1 billion refinancing of the Company's senior secured credit facility,
meaningfully reducing near-term amortization obligations, lowering the weighted average cost of debt, and providing committed capital to redeem the Company's 6.125% Senior Notes due 2028 following the call premium expiration in August 2026.
In April 2026, completed the disposition of the Company's remaining custom rehabilitation assets, further concentrating the Company's portfolio around its core Sleep and Respiratory Health businesses.
All comparisons are to the quarter ended March 31, 2025 unless otherwise stated.
Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%.
Organic revenue growth of 9.1%, with growth across each of the reportable Segments.
Net loss attributable to AdaptHealth Corp. was $16.0 million compared to net loss of $7.2 million.
Adjusted EBITDA was $121.2 million compared to $127.9 million, a decrease of 5.3%.
Cash flow from operations was $93.7 million, a slight decrease from $95.5 million, and free cash flow was negative $27.5 million, compared to negative $0.1 million.
"The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth," said Suzanne Foster, Chief Executive Officer. "We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance, with broad-based organic growth across all four
segments. Although we incurred elevated labor costs to execute the transition responsibly, we are already working to optimize the business for our newly attained scale."
For fiscal year 2026, the Company is raising net revenue guidance by $10 million and maintaining Adjusted EBITDA and free cash flow guidance, as follows:
Net revenue of $3.45 billion to $3.52 billion
Adjusted EBITDA of $680 million to $730 million
Free cash flow of $175 million to $225 million
Management will host a teleconference today, Tuesday, May 5, 2026, at 8:30 am ET to discuss the results and business activities with analysts and investors.
Interested parties may participate in the call by dialing:
833-316-2483 (Domestic) or
785-838-9284 (International)
When prompted, reference Conference ID: AHCO1Q26
Webcast registration: Click here
Following the live call, a replay will be available for six months on the Company's website, https://www.adapthealth.com, under "Investor Relations."
AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical
equipment, medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The
Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and
related services to patients for the treatment of diabetes. The Wellness at Home segment provides home medical
equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex
disease states by providing essential medical supplies and durable medical equipment.
The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of
Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.5 million patients annually in all 50 states through its network of approximately 670 locations in 48 states.
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company's acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for
illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or
impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.
These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company's operations, result in adverse judgments,
settlements or fines and create negative publicity; changes in the Company's customers' preferences, prospects and the competitive conditions prevailing in the healthcare sector. A further description of such risks and uncertainties can be found in the Company's filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that
could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-
looking statements reflect the Company's expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
The Company uses EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, free cash flow and organic revenue, which are financial measures that are not in accordance with generally accepted accounting principles in the United States, or
U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. In addition, the Company's ability to incur additional indebtedness and make investments under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA.
The Company believes Adjusted EBITDA and Adjusted EBITDA Margin are useful to investors in evaluating the Company's financial performance. The Company uses Adjusted EBITDA as the profitability measure in its incentive
compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements.
EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant
components in understanding and assessing financial performance. Accordingly, these key business metrics have
limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity.
The Company uses free cash flow, which is a financial measure that is not in accordance with U.S. GAAP, in its
operational and financial decision-making and believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the Company's competitors and to measure the ability of companies to service their debt. The Company's presentation of free cash flow should not be construed as a measure of liquidity or discretionary cash available to the Company to fund its cash needs, including investing in the growth of its business and meeting its obligations.
Free cash flow should not be considered as a measure of financial performance under U.S. GAAP. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to any performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity.
The Company uses organic revenue, which is a financial measure that is not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that it is useful to investors, as a supplement to U.S. GAAP measures. The change in net revenue from organic revenue is reported as
organic revenue as a percentage of prior period total reported net revenue. Management believes organic revenue is meaningful to investors as it provides appropriate visibility into how the Company changes organically-that is, within its existing operations using its own resources.
Organic revenue is defined as all changes in reported net revenues from the comparable period presented, excluding: (1) increases in net revenue in the current period from acquisitions attributable to businesses and/or assets the Company has owned for less than one year based on the month of acquisition. This excludes the acquisition of assets from previous providers to facilitate the transition of patients related to newly awarded at-risk capitated contracts, since the revenue
related to these agreements is earned organically; and (2) decreases in net revenue from dispositions existing in the prior period from divested product lines, services, and/or businesses for which there is no revenue recognized in the current
period.
This release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results.
Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result,
reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available
without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results.
In addition, the Company's financial guidance in this release excludes the impact of any potential additional future
strategic acquisitions and any items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.
(in thousands)
March 31, 2026
December 31, 2025
Assets
Current assets:
Cash
$ 47,964
$ 106,136
Accounts receivable
391,966
370,897
Inventory
159,269
151,247
Prepaid and other current assets
88,277
100,619
Total current assets
687,476
728,899
Equipment and other fixed assets, net
622,185
509,956
Operating lease right-of-use assets
122,972
111,968
Finance lease right-of-use assets
49,918
52,300
Goodwill
2,567,365
2,541,428
Identifiable intangible assets, net
80,232
85,121
Deferred income taxes, net
275,061
267,786
Other assets
18,798
19,119
Total Assets
$ 4,424,007
$ 4,316,577
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses
$ 601,392
$ 553,700
Current portion of long-term debt
24,375
20,313
Current portion of operating lease obligations
34,035
30,728
Current portion of finance lease obligations
19,863
17,702
Contract liabilities
59,729
59,843
Other liabilities
3,893
30,106
Total current liabilities
743,287
712,392
Long-term debt, less current portion
1,798,902
1,715,983
Operating lease obligations, less current portion
93,528
85,470
Finance lease obligations, less current portion
30,004
32,604
Other long-term liabilities
243,805
243,804
Total Liabilities
2,909,526
2,790,253
Total Stockholders' Equity
1,514,481
1,526,324
Total Liabilities and Stockholders' Equity
$ 4,424,007
$ 4,316,577
Three Months Ended
(in thousands, except per share data) March 31,
2026
2025
Net revenue
$ 819,799
$ 777,882
Costs and expenses:
Cost of net revenue
708,298
657,444
General and administrative expenses
95,908
86,854
Depreciation and amortization, excluding patient equipment
depreciation 10,104 10,414
Total costs and expenses
814,310
754,712
Operating income
5,489
23,170
Interest expense, net
25,594
28,399
Loss before income taxes
(20,105)
(5,229)
Income tax (benefit) expense
(5,232)
850
Net loss
(14,873)
(6,079)
Income attributable to noncontrolling interest
1,167
1,128
Net loss attributable to AdaptHealth Corp.
$ (16,040)
$ (7,207)
Weighted average common shares outstanding - basic
135,779
134,799
Weighted average common shares outstanding - diluted
135,779
134,799
Basic net loss per share
$ (0.12)
$ (0.05)
Diluted net loss per share
$ (0.12)
$ (0.05)
Three Months Ended
March 31,
(in thousands)
2026
2025
Cash flows from operating activities:
Net loss
$ (14,873)
$ (6,079)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation
106,469
94,345
Equity-based compensation
6,532
5,296
Reduction in the carrying amount of operating lease right-of-use assets
10,659
7,490
Reduction in the carrying amount of finance lease right-of-use assets
5,046
3,374
Deferred income tax benefit
(5,600)
(776)
Amortization of deferred financing costs
1,186
1,283
Writeoff of fixed assets
691
-
Other
(786)
-
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable
(21,069)
(15,429)
Inventory
(7,751)
9,159
Prepaid and other assets
11,913
194
Operating lease obligations
(10,298)
(7,861)
Operating liabilities
11,603
4,531
Net cash provided by operating activities
93,722
95,527
Cash flows from investing activities:
Purchases of equipment and other fixed assets
(121,212)
(95,585)
Payments for business acquisitions
(84,683)
-
Proceeds from the sale of assets
1,439
-
Net cash used in investing activities
(204,456)
(95,585)
Cash flows from financing activities:
Repayments on long-term debt and lines of credit
(14,063)
(25,000)
Proceeds from borrowings on lines of credit
100,000
-
Repayments of finance lease obligations
(3,104)
(3,221)
Proceeds received in connection with employee stock purchase plan
464
564
Payments relating to the Tax Receivable Agreement
(26,846)
(25,012)
Distributions to noncontrolling interests
(1,522)
(2,046)
Payments for tax withholdings from vesting of restricted stock units
(2,367)
(1,324)
Net cash provided by (used in) financing activities
52,562
(56,039)
Net decrease in cash
(58,172)
(56,097)
Cash at beginning of period
106,136
109,747
Cash at end of period
$ 47,964
$ 53,650
EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin
This press release presents AdaptHealth's EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin for the three months ended March 31, 2026 and 2025.
AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient equipment depreciation.
AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus equity-based compensation expense, litigation settlement expense, and other non-recurring items of expense or income.
AdaptHealth defines Adjusted EBITDA Margin as Adjusted EBITDA (as defined above) as a percentage of net revenue.
The following unaudited table presents the reconciliation of net loss attributable to AdaptHealth Corp. to EBITDA and Adjusted EBITDA, and the reconciliation of net loss attributable to AdaptHealth Corp. as a percentage of net revenue to Adjusted EBITDA Margin, for the three months ended March 31, 2026 and 2025:
Three Months Ended March 31, 2026 2025
(in thousands, except percentages)
Dollars
Revenue Percentage
Dollars
Revenue Percentage
Net loss attributable to AdaptHealth Corp.
$ (16,040)
(2.0)%
$ (7,207)
(0.9)%
Income attributable to noncontrolling interest
1,167
0.2%
1,128
0.1%
Interest expense, net
25,594
3.1%
28,399
3.7%
Income tax (benefit) expense
(5,232)
(0.6)%
850
0.1%
Depreciation and amortization, including patient equipment depreciation
106,469
13.0%
94,345
12.1%
EBITDA
111,958
13.7%
117,515
15.1%
Equity-based compensation expense (a)
6,532
0.8%
5,296
0.7%
Litigation settlement expense (b)
500
0.1%
-
-%
Other non-recurring expenses, net (c)
2,203
0.2%
5,127
0.6%
Adjusted EBITDA
$ 121,193
14.8%
$ 127,938
16.4%
Adjusted EBITDA Margin
14.8%
16.4%
Represents equity-based compensation expense for awards granted to employees and non-employee directors.
Represents an estimated expense to settle a shareholder derivative complaint.
The 2026 period consists of $1.6 million of consulting expenses associated with asset dispositions and
$0.9 million of transaction costs associated with acquisitions, partially offset by $0.3 million of other net non-recurring income. The 2025 period consists of $2.3 million of consulting expenses associated with asset
dispositions, $1.6 million of consulting expenses associated with systems implementation activities, and
$1.2 million of other non-recurring expenses.
Free Cash Flow
This press release presents AdaptHealth's free cash flow for the three months ended March 31, 2026 and 2025.
AdaptHealth defines free cash flow as net cash provided by operating activities less cash paid for purchases of equipment and other fixed assets.
The following unaudited table reconciles net cash provided by operating activities to free cash flow for the three months ended March 31, 2026 and 2025:
Three Months Ended
(in thousands) March 31,
Net cash provided by operating activities
$ 93,722 $
95,527
Purchases of equipment and other fixed assets
(121,212) (95,585)
Free cash flow
$ (27,490) $ (58)
Contacts
AdaptHealth Corp. Jason Clemens, CFA Chief Financial Officer
Luke Montgomery, CFA
Senior Vice President, Investor Relations [email protected]
Disclaimer
AdaptHealth Corp. published this content on May 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 05, 2026 at 13:34 UTC.